The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer

Journal of Clinical Medicine
Ludivine DionVincent Lavoué

Abstract

Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. Approximately 15% of all EOCs are due to BRCA1 or BRCA2 mutations. Four histologic subtypes characterized by different mutations have been described: serous, endometrioid, mucinous, and clear-cell. Between 20-30% of high-grade serous EOCs have a BRCA mutation. Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors. Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). A universally accepted molecular definition of BRCAness is required to identify optimal theranostic strategies involving PARP inhibitors. Gene expression analyses have led to ...Continue Reading

References

Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chih-Yi HsuIe-Ming Shih
Nov 18, 2005·Gynecologic Oncology·Yasunori HashiguchiSamuel C Mok
Feb 18, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sining ChenGiovanni Parmigiani
Dec 7, 2006·Journal of the National Cancer Institute·Harvey A RischSteven A Narod
Apr 23, 2009·Molecular Oncology·Henry T LynchAndrew K Godwin
Oct 2, 2009·Lancet·Bryan T HennessyMaurie Markman
Jan 6, 2010·EMBO Molecular Medicine·Ana M Mendes-PereiraAlan Ashworth
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Aug 5, 2011·Drugs·R Wendel Naumann, Robert L Coleman
Nov 22, 2011·The Journal of Pathology·Siân JonesIe-Ming Shih
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators
Aug 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhigang C WangUrsula A Matulonis
Dec 22, 2012·The Journal of Clinical Investigation·Roel G W VerhaakUNKNOWN Cancer Genome Atlas Research Network
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susana Banerjee, Stanley B Kaye
Jun 15, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Melissa K McConechyDavid G Huntsman
Nov 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathryn P PenningtonElizabeth M Swisher
Apr 29, 2014·Lancet·Gordon C JaysonJonathan A Ledermann
Aug 6, 2014·Gynecologic Oncology·Koah R VierkoetterKeith Y Terada
Oct 2, 2014·Journal of the National Cancer Institute·Gottfried E KonecnyEllen L Goode
May 29, 2015·Nature·Ann-Marie PatchDavid D L Bowtell
Sep 1, 2015·International Journal of Cancer. Journal International Du Cancer·Elodie ManiéMarc-Henri Stern
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junzo HamanishiIkuo Konishi
Oct 24, 2015·Nature Reviews. Cancer·David D BowtellFrances R Balkwill
Dec 10, 2015·International Journal of Oncology·Kentaro NakayamaSatoru Kyo
Jan 1, 2016·JAMA Oncology·Barbara M NorquistMichael J Birrer
Apr 16, 2016·Nature Reviews. Cancer·Suzanne L TopalianDrew M Pardoll
Oct 25, 2016·Gynecologic Oncology·Anis KaldawySteven A Narod
Nov 30, 2016·Current Opinion in Obstetrics & Gynecology·Paul T Kroeger, Ronny Drapkin
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stefan KommossJacobus Pfisterer
Jul 25, 2018·Molecular Cancer Research : MCR·Takeshi FukumotoRugang Zhang
Aug 16, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephanie LheureuxAmit M Oza
Oct 23, 2018·The New England Journal of Medicine·Kathleen MoorePaul DiSilvestro
May 18, 2019·CA: a Cancer Journal for Clinicians·Stephanie LheureuxAmit M Oza
Jul 26, 2019·Gynecologic Oncology·Paulina CybulskaBritta Weigelt
Nov 26, 2019·American Journal of Clinical Oncology·Eric I MarksDon S Dizon
Dec 19, 2019·The New England Journal of Medicine·Isabelle Ray-CoquardUNKNOWN PAOLA-1 Investigators
Jan 7, 2020·Gynecologic Oncology·Kylie L GorringeClare L Scott

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts

Clinical Trials Mentioned

NCT01849874

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Related Papers

Journal of Gynecology Obstetrics and Human Reproduction
Vincent LavouéThibault de la Motte Rouge
Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Ying Chen, Hui Du
© 2021 Meta ULC. All rights reserved